Which medication is classified as a second-line treatment for allergic conjunctivitis?

Opatanol is correctly identified as a second-line treatment for allergic conjunctivitis. It contains the active ingredient olopatadine, which is an antihistamine that helps relieve symptoms such as itching and redness in the eyes. While it can be effective for the management of allergic conjunctivitis, it is usually considered after first-line treatments—primarily oral antihistamines or topical mast cell stabilizers like sodium cromoglycate—do not provide adequate relief or when the condition is more persistent or severe.

Topical corticosteroids, while effective in managing inflammation, are generally reserved for more severe cases of allergic conjunctivitis due to their potential side effects with prolonged use, such as elevated intraocular pressure or cataract formation. Therefore, Opatanol serves as a useful option when first-line therapies do not suffice, striking a balance between effectiveness and safety for mild to moderate cases of allergic conjunctivitis.